INTRODUCTION AND OBJECTIVES: Evaluation of genetic divergence among primary (P) and metastatic (M) tumors in renal cell carcinoma (RCC) is limited to small or unmatched P-M cohorts. We aim to better characterize somatic mutation (SM) disparities in a cohort of matched P-M tumors.
METHODS: We prospectively sequenced 47 clear cell RCC (ccRCC) and 12 non-clear cell RCC (nccRCC) P-M matched pairs using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a custom 410-gene (previously 341) next-generation sequencing assay.
RESULTS: We detected 527 SM, with a mean (SD) of 4.5 (3.13) per sample. Overall concordance rate (shared mutations/total mutations) was 49% (46% for ccRCC vs 78% for nccRCC). Private mutations in the P tumors were present in 32 (68%) and 3 (25%) of the ccRCC and nccRCC cohorts, respectively. Private mutations in the M tumors were present in 32 (68%) of the ccRCC and in 3 (25%) of nccRCC patients ( Figure 1a ). Strikingly, SETD2 mutations were private to the M or the P in 70% (16/23), and PTEN alterations were private to the M in 66% (4/6). There were no shared ROS1 mutations, and 83% (5/6) of these were private to the M. In a patient-by-patient analysis, 17% (10) of the pairs shared all SM; 15% (9) shared all of the SM in the M, with only private SM in the P; 25% (15) shared all SM in the P, with private SM only in the M; 42% (25) shared SM in the P-M; and some SM were private to either the P or the M. Only 14 pairs showed two SM in the same gene ( Figure 1b) ; in 57% (8) the M presented a mutation in the same gene as the P but on a different location (convergent evolution), in 28% (4) the M presented both the mutation observed in the P and an additional mutation in the same gene (evolution of metastasis), and in 14% (2) the M showed a subclone of the SM observed in the P (subclonal seeding). CONCLUSIONS: Our data suggest that both linear and parallel progression of metastases is observed in RCC. Although the absence of shared SM in matched pairs may be explained by tumor heterogeneity, metastasis-specific SM may represent cells of the P tumor with advantages to develop metastatic disease giving growth advantages in the studied samples. The extent to which the identified mutations contribute to the development of characteristics of metastatic spread needs to be analyzed further.
INTRODUCTION AND OBJECTIVES:
Discovery and understanding of the molecular drivers of clear cell renal cell carcinoma (ccRCC) has led to the development of targeted therapies. Despite advances in these agents, metastatic disease remains largely incurable. Exploration of the biology of metastatic tumors may provide insights into patterns and routes of metastases that could lead to the identification of differences in therapeutic vulnerabilities. We aim to evaluate somatic mutations (SM) associated with organ tropism in a cohort of metastatic ccRCC patients.
METHODS: We identified all patients with ccRCC who had a metastatic tumor sequenced at our institution from 2001 to 2016 using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a next-generation sequencing assay studying a custom panel of 410 (previously 341) targetable genes commonly mutated in cancer. Fishers exact test was used to evaluate associations between recurrent SM and sites of metastasis.
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